Abstract
Lung adenocarcinoma patients have variable prognosis due to many factors. Detection of epidermal growth factor receptor (EGFR) activating mutations is one of the factors that implies the need for initiating a first-line EGFR tyrosine kinase inhibitor (TKI) treatment. However, T790M resistance mutation emergence during treatment accounts for most EGFR-TKI drug resistance. The traditional sample taken for T790M mutation analysis is tissue biopsy, but its numerous disadvantages have introduced liquid biopsy as a preferred method for testing. We studied the prevalence of T790M mutation among pulmonary adenocarcinoma patients in Lebanese patients based on liquid biopsy testing the circulating tumor DNA (ctDNA). We have reviewed the laboratory charts of 52 patients who developed resistance on treatment and referred to AUBMC for EGFR T790M Liquid Biopsy to analyze the mutational analysis results for EGFR T790M. In total, 82.6% of the tested lung cancer patients were positive for a specific EGFR mutation. Among these patients, a total 26.9% were positive for T790M, which is comparable to the international prevalence of this mutation. However, for those cases who developed resistance with circulating DNA showing an EGFR mutation, 50% were positive for T790M that is also comparable to the international literature. This is the first report from Lebanon to discuss the prevalence of T790M mutation using liquid biopsy among Lebanese population. An important landmark molecular epidemiology study that will be a reference to all oncologists in Lebanon and the region in assessing the potential for targeted therapy options in the country. In addition, the data will be of an asset to the building international literature related to this disease.
Similar content being viewed by others
References
Fakhoury H, Noureddine S, Chmaisse HN, Tamim H, Makki RF (2012) MMP1-1607(1G > 2G) polymorphism and the risk of lung cancer in Lebanon. Ann Thorac Med 7(3):130–132
Ansari J, Yun JW, Kompelli AR, Moufarrej YE, Alexander JS, Herrera GA, Shackelford RE (2016) The liquid biopsy in lung cancer. Genes Cancer 7(11–12):355–367
Su K, Chen H, Li K, Kuo M, Yang J, Chan W, Ho B, Chang G, Shih J, Yu S, Yang P (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non–small-cell lung cancer. Journal of Clinical Oncology 30(4):433–440
Bean J, Brennan C, Shih J-Y, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang W-C, Yu C-J, Gazdar A, Pass H, Rusch V, Gerald W, Huang S-F, Yang P-C, Miller V, Ladanyi M, Yang C-H, Pao W (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. PNAS 104(52):20932–20937
Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(4):3–8
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10(8):472–484
Fan G, Zhang K, Ding J, Li J (2017) Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. https://doi.org/10.18632/oncotarget.15412
Oxnard G, Thress K, Alden R, Lawrance R, Paweletz C, Cantarini M, Yang J, Carl Barrett J, Jänne P (2016) Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol 34(28):3375–3382
Thress K, Brant R, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett C (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90(3):509–515
Sun W, Yuan X, Tian Y, Wu H, Xu H, Hu G, Wu K (2015) Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. J Hematol Oncol 8(95):1–9
Sholl L, Aisner D, Allen T, Beasley M, Cagle P, Capelozzi V, Dacic S, Hariri L, Kerr K, Lantuejoul S, Mino-Kenudson M, Raparia K, Rekhtman N, Roy-Chowdhuri S, Thunnissen E, Tsao M, Vivero M, Yatabe Y (2016) Liquid biopsy in lung cancer a perspective from members of the pulmonary pathology society. Arch Pathol Lab Med 140(8):825–829
Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, Matsumoto T, Nagata K, Otsuka K, Tachikawa R, Tomii K, Kunimasa K, Iwasaku M, Nishiyama A, Ishida T, Nishimura Y (2013) Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Cancer 119(24):4325–4332
Karlovich C, Goldman J, Sun J-M, Mann E, Sequist L, Konopa K, Wen W, Angenendt P, Horn L, Spigel D, Soria J-C, Solomon B, Camidge R, Gadgeel S, Paweletz C, Wu L, Chien S, O’Donnell P, Matheny S, Despain D, Rolfe L, Raponi M, Allen A, Park K, Wakelee H (2016) Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a Phase I Study of Rociletinib (CO-1686). Clin Cancer Res 22(10):2386–2395
Wang S, Han X, Hu X, Wang X, Zhao L, Tang L, Feng Y, Wu D, Sun Y, Shi Y (2014) Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta 430:63–70
Usui K, Yokoyama T, Naka G, Ishida H, Kishi K, Uemura K, Oshashi Y, Kunitoh H (2019) Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial). Jpn J Clin Oncol. https://doi.org/10.1093/jjco/hyz023
Shin DH, Shim HS, Kim TJ, Park HS, Choi YL, Kim WS, Kim L, Chang SH, Song JS, Han JH, Lee CH (2019) Provisional guideline recommendation for EGFR gene mutation testing in liquid samples of lung cancer patients: a proposal by the Korean Cardiopulmonary Pathology Study Group. J Pathol Transl Med. https://doi.org/10.4132/jptm.2019.02.22
Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, Zhang HP, Luo L, Zhang J, Tang L, Su B, Chen G, Zhu G, Gu Y, Xu JF (2016) Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep 6:2045–2322
Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T, McCormack R (2014) Gefitinib treatment in EGFR mutated caucasian NSCLC circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 9(9):1345–1353
Kuang Y, Rogers A, Yeap B, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel R, Jänne P (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15(8):2630–2636
Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P (2014) Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib. Cancer 120(24):3896–3901
KobayashI S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance ofnon-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors do not have any conflict of interest to declare.
Ethical approval
The study was approved by the Institutional Review Board of the American University of Beirut Medical Center as a retrospective chart review and data collection with waiver of informed consent.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Assi, H., Tfayli, A., Assaf, N. et al. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center. Mol Biol Rep 46, 3671–3676 (2019). https://doi.org/10.1007/s11033-019-04797-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-019-04797-5